Genetic Heterogeneity and Challenges in the Management of Permanent Neonatal Diabetes Mellitus: A Single-Centre Study from South India

Sophy Korula, Lavanya Ravichandran, Praveen G. Paul, Jabasteen Johnson, Aaron Chapla, Sridhar Santhanam, Anna Simon, Sarah Mathai

Department of Paediatrics, Paediatric Unit-1, Paediatric Endocrinology and Metabolism Division, Christian Medical College and Hospital, 1Department of Endocrinology, Diabetes and Metabolism, Christian Medical College and Hospital, 2Department of Neonatology, Christian Medical College and Hospital, Vellore, Tamil Nadu, India

Abstract

Aim and Objectives: 1. To study the clinical outcome, growth and glycaemic control, 2. To study the frequency and type of genetic mutations.

Methods: This is a retrospective study with a review of data of medical records from 2008 till date. Results: Twelve patients (six males) with neonatal diabetes mellitus (NDM) were identified. Median (interquartile range – (IQR)) age at diagnosis was 72 (31–95) days with a history of consanguinity in 75%. The median birth weight (range) was 2345 (900–3300) g. Follow-up data were available for eight patients with a median age at (IQR) follow-up of 3.3 (3–5.3) years. At follow-up, the mean annual HbA1c was 8.2% at a mean insulin dose of 1.1 U/kg/d. One patient with Wolcott-Rallison syndrome (WRS) and 21-hydroxylase deficiency had poor growth and intellectual difficulty. The rest demonstrated satisfactory growth with an increase of mean weight centile from 2nd to 13th, height centile from 6.5th to 20th and normal neuro-cognitive development. Eleven patients underwent genetic testing with a molecular diagnosis in 54% (6/11): EIF2AK3 (n = 2) and one each in INS, PDX1, IL2RA and FOXP3. None had variants in ABCC8 or KCNJ11. One with immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome underwent haematopoietic stem cell transplant (HSCT) and later succumbed. Conclusion: Our study demonstrates good clinical outcomes among NDM patients without immune dysfunction. Molecular diagnosis was attained only in around half of the patients (54%) with a great genetic heterogeneity.

Keywords: Monogenic diabetes, Neonatal diabetes, NDM, Wolcott-Rallison syndrome, IPEX syndrome, Insulin, diabetes management

INTRODUCTION

Neonatal diabetes mellitus (NDM) is a rare genetic disorder that occurs at a frequency of 1 in 90,000[1] in European countries to 1 in 21,000[2] in the Middle-East. It is defined as the onset of diabetes mellitus within 6 months of age. There are two well-recognized forms of NDM: transient and permanent. These neonates require intensive treatment with insulin to ensure optimal glycaemic control while maintaining a fine balance to prevent hypoglycaemia which can be detrimental to their neurological outcome. Genetic analysis helps in establishing the diagnosis of permanent diabetes mellitus (PDM) and has a bearing on the mode of further management. A comprehensive genetic review noted an 80% detection rate of aetiological mutations in NDM.[3] Infants with potassium channel-related genetic defects in KCNJ11 or ABCC8 can be changed over to oral glibenclamide therapy easing the burden of daily insulin injections on the family. Genetic testing also helps with the screening of associated defects and determines the need for stem cell transplant in rare forms of NDM.

In developing countries, the lack of standardized genetic testing labs and funds often results in many children missing out on testing altogether. Our centre is unique in that regard...
as most of our genetic tests are done in-house and thus are fairly affordable. Paediatric endocrinology and endocrine genetic testing being under one roof does brings in many referrals to our centre from the country. Our aim is to study the clinical profile and genetic data in our cohort with NDM. Further, we would like to analyse their outcome and highlight how we overcame some of the challenges faced during management.

**Methods**

This is a retrospective observational study enrolling all children diagnosed or treated for NDM in our centre from 2008 till date. The study was conducted in a tertiary health care centre from South India. The study was cleared by the institutional review board and ethics committee (IRB Min No. 12739). A waiver for consent was obtained from the IRB.

All patients had been tested for anti-tyrosine phosphatase (anti-IA2) and anti-glutamic acid decarboxylase (anti-GAD) antibodies. The in-house genetic testing included analysis for 30 genes (Appendix 1) using next-generation sequencing technique and validated on Sanger sequencing as published earlier.[4] The mean annual HbA1c for each patient was calculated by taking the average of all available HbA1c values over the last year. The weight and height centiles were calculated using the World Health Organization (WHO) growth charts.

Data were collected from an online medical records portal and entered into Microsoft Excel for analysis. Normality of distribution was evaluated using the Shapiro–Wilk test. The continuous variables were expressed as mean ± SD for normally distributed variables or as median (interquartile range – [IQR]) for not normally distributed variables whereas categorical variables were expressed as absolute numbers or percentages as appropriate.

**Results**

A total of 12 patients (six males) were identified. A summarized table with the clinical and genetic data is attached [Table 1].

**Clinical and biochemical characteristics at onset**
The median age at diagnosis was 72.5 days with the earliest diagnosis at day 14 and the latest on day 180. Ten were born at term whereas two were born preterm at 33 and 34 weeks of gestation, respectively. Of the 12, three neonates were inborn. The median birth weight of our cohort was 2345 g with the lowest being 900 g. Eight (75%) were born to consanguineous parents. Five mothers had a poor obstetric history with at least one previous abortion and one family having two late neonatal deaths. The median (IQR) age at presentation to our centre was 73.5 days (31–188).

Of the 12, seven were managed with subcutaneous (SC) insulin (five of the seven outborn infants were already initiated on SC insulin prior to presentation at our centre). Insulin infusion at a low dose of 0.05 U/kg/h was used among five infants at presentation with diabetic ketoacidosis (DKA). They were shifted to SC insulin as soon as the acidosis normalized. Various regimes of SC insulin were given. In two of our patients with 880 g and 1120 g at presentation, we used rapid-acting analogues diluted in normal saline initially.[4] This required training of the nursing staff and adhering to a protocol to avoid dosage errors. In patient 2, the neonate was 970 g at presentation. For the first 5 days, intermittent intravenous (IV) boluses of regular insulin at 0.1 U/kg were given when glucometric values were > 250 mg/dl, as there was hardly any SC tissue for insulin delivery and only available access was IV. This necessitates the treating endocrinologist to take into consideration the minimal fat available for insulin administration resulting in variable absorption[5] and the feeding regime that the neonate is on. Later, diluted glargine once a day was used as reported earlier[6] and subsequently changed to undiluted glargine once daily using a pen device. Two other patients were managed with SC isophane insulin once to twice daily and regular insulin if needed, as also suggested by an earlier review.[6] Although developing countries pose a hurdle with lack of insulin pumps for an optimal basal-bolus pattern as described in the literature,[7] our data highlights that SC insulin dosing can be attempted and was successful even in extremely low birth weight neonates.

Median plasma glucose at presentation was 390 mg/dl with the highest being 1308 mg/dl. Islet tyrosine phosphatase 2 antibody (IA2 antibody) was negative in all. Antibody to glutamic acid decarboxylase (GAD antibody) was positive in the patient with IL2RA mutation [patient 9 in Table 1]. The median duration of in-hospital stay at presentation was 8 days (3–65).

**Follow-up data**

A total of 12 patients were diagnosed with NDM [Table 1]. Ten continued treatment here, one who was advised haematopoietic stem cell transplant (HSCT) did not come for further endocrine or transplant team follow-up (patient 9) and one patient got discharged against advice (patient 10). Two infants have follow-up < 6 months (patients 11 and 12) and patient 11 expired under unclear circumstances at home. Follow-up data from eight infants was analysed. The median follow-up age was 3.3 years and the longest follow-up was at age 12.1 years.

- **Glycaemic status and other diabetes-related complications**
  
  Six are on basal-bolus (with glargine and regular) and two on the split-mix regime (with regular and isophane insulin) with a mean dose of 1.1 U/kg/d. The median HbA1c is 8.8% (6.5–10.3) at the last follow-up with 1 year average of 8.2%. None are on oral glibenclamide treatment.

  Patient 1 was readmitted with DKA and pneumonia at 7 months of age when insulin infusion (0.05 U/kg/h) was instituted briefly. Patient 3 was admitted at 6 months of age with recurrent asymptomatic hypoglycaemia following a viral illness and was discharged after 3 days. Patient 7 was admitted with typhoid fever at 3 years of age. Patients 1 and 6 with a duration of diabetes > 5 years
### Table 1: Summary of clinical characteristics, genotype and follow-up details

| S.No | Age at diagnosis (days) | Age at presentation (days) | Gender | GA (wks) | Birth weight (grams) | HbA1c (initial) | Family history | Genetic mutation | Insulin dose (U/kg/d) | Age at last follow-up (yrs) | HbA1C (Av/yr) | Other co-morbidity | Outcome |
|------|------------------------|----------------------------|--------|----------|----------------------|----------------|----------------|-----------------|----------------------|--------------------------|----------------|----------------|---------|
| 1    | 14                     | 14                         | F      | 37       | 1960                 | 8.1            | C G6P1L1 A3MTP1 | Negative, (Heterozygous HADH VOUS) | 0.8                  | 12.1                     | 8.3            | Nil            | Well, DM complications screen neg |
| 2    | 21                     | 21                         | F      | 34       | 900                  | 9             | C G2A1 (this neonate born of a twin pregnancy- 1 twin passed away) | Negative, (2 heterozygous Variants-ZFP57 variant c. 1348G>A (p. Gly450Arg) & a WFS1 variant c. 1406C>T (p. Ser469Leu)) | 1.2                  | 3.2                      | 8              | Nil            | Well |
| 3    | 14                     | 14                         | M      | 33       | 1120                 | 7.2            | NC G3P2L2      | Negative          | 0.4                  | 3.2                      | 6.6            | Nil            | Well |
| 4    | 34                     | 34                         | F      | 41       | 2130                 | 10.2           | NC G2P1L1      | Negative          | Not done             |                         |                |                | DAMA |
| 5    | 110                    | 110                        | M      | 40       | 2600                 | 13.4           | C G2A1         | Negative          | 1.1                  | 3.7                      | 8.9            | Nil            | Well |
| 6    | 180                    | 210                        | M      | 40       | 3000                 | 8.8            | NC G1          | Insulin gene heterozygous mutation c265C>T | 0.2                  | 3.5                      | 7.4            | Nil            | Well |
| 7    | 90                     | 330                        | F      | 40       | 3000                 | 7.1            | C G2P1L1      | EIF2AK3 homozygous variant c. 1763G>A, exon 10 | 1.9                  | 9.8                      | 8.1            | CAH intellectual disability, short stature, Turner mosaicism | Well, DM complication screen neg |
| 8    | 70                     | 72                         | F      | 37       | 2300                 | 11.3           | C G3P2L2      | Homozygous 2-bp deletion (1758_1759delAT) in the EIF2AK3 gene | 0.6                  | 3.2                      | 8.4            | Nil, no skeletal changes so far | Well |
| 9    | 120                    | 180                        | M      | 38       | 2390                 | 6.5            | C G2A1         | Homozygous IL2RA missense variant | 1                   |                         |                | Immune-deficiency with chronic diarrhoea, poor weight | Lost to follow-up |
| 10   | 90                     | 210                        | M      | 40       | 3300                 | 9              | NC G5P4A2L2   | Hemizygous FOXP3 missense variant c. 1150G>A | 1.8                  | 1.8                      | 9.6            | IPEX syndrome-chronic diarrhoea and hypothyroidism from 3 months of age, post HSCT | Transplant failed, passed away at home at 26 months of age |
| 11   | 75                     | 75                         | M      | 40       | 2500                 | 7.6            | C G1           | Homozygous PDX1 c. 533A>G, exon 2 | Negative          |                         |                | Died at home, unclear cause | Alive, not completed 6 months follow-up |
| 12   | 38                     | 38                         | M      | 40       | 1800                 | 10.5           | C G1           | Negative          |                         |                         |                |                | |

DM=Diabetes mellitus. GA=Gestational age. C=Consanguineous. NC=Non-consanguineous. DAMA=Discharged against medical advice
are negative for nephropathy and retinopathy screen. There were no other diabetes-related events requiring hospitalization.

- **Growth**

  At the first visit, their average weight and length centiles were 1.6 and 5.8. Patient 6 with Wolcott-Rallison syndrome (WRS) with skeletal dysplasia has poor growth with a velocity of only 3 cm/year and has a height of 105 cm at 9 years of age. Among the remaining, there was a significant increase in mean weight centile from 2nd to 13th and in mean length/height percentile from 6.5 to 20, as per WHO growth chart measurements, indicative of good growth catch-up on treatment. All of them had satisfactory age-appropriate growth velocity - 13 cm/year (at age 2–3 years) and 6 cm/year (>3 years).

- **Development**

  Patient 6 with WRS had a complicated medical course with an initial diagnosis of salt-losing 21α-hydroxylase deficiency at 1 week of life and later of NDM at 2 months age. She has intellectual concerns and plans to undergo a formal neuro-cognitive assessment. The remaining seven patients have normal development at follow-up. Patient 1 is currently studying in class 7 and doing well.

**Genetic mutation analysis**

Eleven underwent genetic testing (eight - in-house, two - Exeter, one - external lab in India). Mutation analysis confirmed diagnosis in 6/11 (54%) with pathogenic/likely pathogenic variants (*EIF2AK3*-2, one each for *INS, PDX1, IL2RA, FOXP3*) [Table 2]. Variants of unknown significance were seen in 2/11 (*ZFP57* variant of uncertain significance, *HADH* heterozygous mutation in 1); negative in 4/11. Table 2 highlights the classification of the genetic variants. In our cohort, 75% (8/12) were born to consanguineous parentage. Of these, 25% had *EIF2AK3* mutation in keeping with a higher proportion of this mutation seen with consanguinity [Figures 1 and 2].

**Co-morbidity**

Patient 6 has congenital adrenal hyperplasia (CAH) (homozygous I2G variant in *CYP21*) and is on glucocorticoid and mineralocorticoid replacement from early infancy. She has significant short stature. Apart from low-level Turner mosaicism (1.6%) on karyotype, she also has dysplastic changes on a skeletal survey in keeping with her diagnosis of WRS. Patient 8 with immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome was diagnosed to have hypothyroidism and enteropathy from early infancy and was on treatment for same. This child had genetic testing done at Exeter which confirmed *FOX P3* mutation and he was referred to our centre at 7 months of age primarily for a bone marrow transplant. Patient 9 presented at 6 months of age with a diagnosis of *IL2RA* deficiency causing both NDM and recurrent diarrhoea. He was being worked up for a bone marrow transplant but subsequently did not follow up.

Table 2: ACMG 2015 based classification of the variants identified in the study

| Patient no. from Table 1 | Gene symbol | Codon change | Protein change | Genotype | Position | Effect | Novel/ reported | ACMG classification |
|-------------------------|-------------|--------------|----------------|----------|----------|--------|----------------|---------------------|
| 1                       | HADH        | c. 923C>G    | Pro308Arg      | Heterozygous | Exon 9 | Missense | Novel | Variant with uncertain significance |
| 2                       | ZFP57       | c. 1348G>A   | Gly450Arg      | Heterozygous | Exon 5 | Missense | Novel | Variant with uncertain significance |
| 2                       | WFS1        | c. 1406C>T   | Ser469Leu      | Heterozygous | Exon 8 | Reported |        | Variant with uncertain significance (non-diabetic dad also carries same mutation) |
| 6                       | INS         | c. 265C>T    | Arg89Cys       | Heterozygous | Exon 3 | Missense | Reported | Pathogenic |
| 7                       | EIF2AK3     | c. 1763G>A   | Arg588Gln      | Homozygous | Exon 10 | Missense | Reported | Likely pathogenic |
| 8                       | EIF2AK3     | c. 1758_1759del | Ser587ThrfsTer5 | Homozygous | Exon 10 | Frameshift with premature truncation | Novel | Likely pathogenic |
| 10                      | FOXP3       | c. 1150G>A   | Ala384Thr      | Hemizygous | Exon 12 | Missense | Reported | Likely pathogenic |
| 11                      | PDX1        | c. 533A>G    | Gln178Gly      | Homozygous | Exon 2 | Missense | Reported | Likely pathogenic |

ACMG=The American College of Medical Genetics and Genomics
Among the cohort of paediatric diabetes, NDM constitutes a minor percentage of 0.17%. Permanent NDM is caused by monogenic disorders affecting a number of genes that have been comprehensively reported. All infants with NDM are treated with insulin therapy initially and those with positive KCNJ11 or ABCC8 mutations are changed over to oral glibenclamide therapy. There is a scarcity of data with regard to the management and outcome of NDM in resource-limited settings. Our study reports a cohort of 12 patients with NDM for whom follow-up including growth and glycaemic status has been highlighted. The number of patients from a single centre is similar to other studies.

Jain et al. have described follow-up data on 11 infants from north India. The median age at presentation was 8 weeks in this cohort, and at median follow-up age of 27 months, they reported a good outcome with a mean HbA1c of 7%. The study reports a genetic mutation-positive rate of 63.6%. KCNJ11 and ABCC8 mutations were noted in 4/11 (33%). Another study on the south Indian cohort of 10 infants reported a genetic mutation-positive rate of 90%.[11] KCNJ11 and ABCC8 mutations were predominant again accounting for 30% (3/10) of their cohort and these infants have switched over to sulphonylureas accordingly. Data from other case-series also demonstrates a similar genetic distribution with regard to potassium channel defects.[12–17] Interestingly, Dalvi et al. also report a patient with late-onset diabetes having homozygous ABCC8 mutation.[17] More recent literature reports GCK, EIF2AK3 and PTF1A mutations at higher frequency in the middle-eastern population with high consanguinity as compared to the western population where KATP channel mutations are the predominant cause of permanent diabetes.[11,16] Excellent study by Nayak et al. also collated data of all previously published Indian data on NDM which demonstrates the bulk of all NDM cases to be due to potassium ATP (KATP) channel defects – ABCC8 and then KCNJ11.[18] However, WRS from EIF2AK3 mutation still remains the most frequently reported aetiology for permanent neonatal diabetes mellitus (PNDM). This study also describes a unique case of transient NDM with a homozygous ABCC8 mutation. A similar report of a high percentage of WRS has been recently reported from Egypt as well.[19] This is in keeping with consanguineous and inbred population cohorts demonstrating the same finding.[20] Interesting is also the fact that in a recent study on monogenic diabetes from another centre in South India, all patients with WRS had a presentation at 1 year of age or later.[21] Table 3 enlists the salient features of the reported Indian literature on NDM. This highlights the degree of clinical and genetic heterogeneity that exists with regard to NDM – both the KATP channel defects as well as the syndromic forms.

Our cohort had no KCNJ11 or ABCC8 mutations and hence none could be changed over to oral glibenclamide. This is very different from the data published earlier where 46% of cases from consanguineous families had one of the potassium channel mutations[21] and other Indian studies which report at least 30% to have potassium channel mutations.[7,8] This could be attributed to a high degree of consanguinity in the south Indian cohort and referral bias. Perhaps with more prospective data, a better understanding of the same can be elicited.

Interestingly, two of our patients had immune dysfunction. Patient 8 [in Table 1] with IPEX syndrome was referred for HSCT and had required very high doses of insulin up to 2 U/kg/d while on immunosuppression. Unfortunately, he failed the transplant and our team was informed over the phone that he passed away at 26 months of age. Although NDM as part of IPEX is well known, there is very scarce literature on the challenges in the management of this condition. A case-series showed that among those who had immune dysfunction with FOX P3 and NDM – all three patients succumbed within 2 years of age.[22] None of these three received HSCT. The same series also highlights three other patients with NDM without significant immune dysregulation doing fairly well till adolescence, thus depicting clinical heterogeneity within this genotype as well. This clearly highlights the need for more such patients to be reported. Patient 9 also came for an opinion regarding HSCT and had poor weight gain with diarrhoea and was diagnosed with a rare form of NDM secondary to homozygous IL2RA missense mutation. He was also positive for GAD antibody and this association has not been reported so far. Although this genetic mutation is reported in the literature, no case reports of the same have been described.

With premier genetic facilities being available abroad and these labs catering to the needs of other developing countries, we now have excellent published data on genetic mutations available.[3] Nevertheless, both genetic and clinical heterogeneity still remain across all ethnicities. Also, practical management of these patients and outcomes with regard to growth and glycaemic control are poorly described as noted in Table 3. This study is an attempt to bridge that gap and highlights the management of NDM from a developing country perspective.
Table 3: Summary of Indian case-series with NDM

| Study and year | Number of patients with NDM | Genetic mutation distribution | Follow-up period and outcome | Glycaemic control | Growth | Unique features of the study |
|---------------|-----------------------------|-------------------------------|-----------------------------|------------------|--------|-----------------------------|
| Jahnavi et al., 2013, Multi-centre, India | 22 | 22- PDM KCNJ11-3 ABCC8-4 INS - 1 | Follow-up period – not described | Mean HbA1c- 6.8% among five on glibenclamide, Rest- not mentioned | Not reported | Good outcome with sulphonylureas mentioned. |
| Ganesh et al., 2016, Chennai, India | 10 (Five boys) | 9 – PDM, 1-TDM ABCC8-2 KCNJ11-1 INS-2 PDX-1 EIF2AK3-1 NEUROD1-1 SLC1A2-1 | One died Nine followed-up Mean age at follow up – 4.3 years | Not mentioned | Reported to be normal | Predominant (33%) KATP channel mutation reported. |
| Jain et al., 2017, Delhi, India | 11 (Eight boys) | 9- PDM, 2- TDM, 1-uncertain KCNJ11-3 ABCC8-1 INS-2 SLC1A2-1 | Median age at follow up- 2.3 years | Mean HbA1c- 7.1% | Reported to be normal | 63.6% pathogenic mutation rate, Follow-up age and HbA1c highlighted. |
| Dalvi et al., 2017, Mumbai, India | Six | 5-PDM, 1-TDM ABCC8-3 INS-1 EIF2AK3-1 | Nine alive and on follow-up (1.5-10) 3-expired- 1 post-transplant, 1 with neg mutation and 1 with WRS and pneumonia | Not mentioned | Not mentioned | Late manifestation at 9 years for one with homozygous ABCC8 mutation described. Low birth weight not a striking feature. |
| Nayak et al., 2021, Lucknow, India | 12 | 7-PDM, 4-TDM GCK-2 TRMA-2 EIF2AK3-2 FOXp3-1 | Nine alive and on follow-up for all | Not mentioned | Not mentioned | Novel disease causing mutations in EIF2AK3, GCK, ABCC8 described Homozygous ABCC8 presenting as TDM described Excellent summary of genetic data of all previous Indian patients with NDM All syndromic forms included have age on onset 1 year and above (13 with Wolfram, 1 with TRMA, 1 mitochondrial) Association of DEND with ABCC8 mutation described The outcome of NDM in terms of both growth and glycaemic status included Rare forms of immune dysfunction with NDM described No K channel mutation in a cohort |
| Lakshmanan et al., 2021, Cochin, India | 15 | 9-PDM, 6- NDM ABCC8-3 INS-3 KCNJ11-2 | Not mentioned for all | Not mentioned | Not mentioned | |
| Current study, 2021, India | 12 | All PDM EIF2AK3-2 INS-1 PDX-1 FOXp3-1 IL2RA-1 | Eight alive and on follow-up (1.8-12.1 years)*, Median follow-up age 5 years. DAMA 2 died- 1 post-transplant, 1 unclear cause Lost to follow-up | Mean HbA1c – 8.2% (1-year average) | Weight for age from 2nd to 13th percentile Height for age from 6.5 to 20th percentile | |

TDM= transient diabetes mellitus. *Distribution of genetic mutations among PDM in each group alone included in the table. *Age range at follow-up
Limitations
This was a retrospective study cohort with only a 54% genetic mutation-positive rate detected.

Conclusion
Our study demonstrates good growth and glycaemic outcome in NDM patients without immune dysfunction when treated with SC insulin therapy. The use of diluted SC insulin is often necessary for the management of NDM infants. When manufacturer-provided diluents are not available, dilution with normal saline can be used for rapid-acting analogues, regular insulin as well as glargine. The molecular diagnosis was attained in a smaller proportion (54%) of patients with a conspicuous absence of mutations in KCNJ11 and ABCC8, which are in contrast to other Indian or international studies. The major utility of molecular diagnosis to identify sulphonylurea-responsive NDM patients is well known. In this study, we emphasize the role of molecular diagnosis in identifying the need for therapies other than insulin such as HSCT and/or immunosuppressive therapy in NDM patients.

Author contribution
SK- Concept, data collection, analysis, clinical management, manuscript writing, editing
LR- genetic analysis, editing
PGP- clinical management, editing
J- Genetic analysis
AC- Genetic analysis, data collection, editing
SS- clinical management, editing
AS- clinical management, editing
SM- clinical management, editing.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

References
1. Iafusco D, Massa O, Pasquino B, Colombo C, Iughetti L, Bizzarri C, et al. Minimal incidence of neonatal/infancy onset diabetes in Italy is 1: 90,000 live births. Acta Diabetol 2012;49:405–8.
2. Habeb AM, Al-Magamsi MSF, Eid IM, Ali MI, Hattersley AT, Hussain K, et al. Incidence, genetics, and clinical phenotype of permanent neonatal diabetes mellitus in northwest Saudi Arabia. Pediatr Diabetes 2012;13:499–505.
3. Franco ED, Flanagan SE, Houghton JA, Allen HL, Mackay DJ, Temple IK, et al. The effect of early, comprehensive genomic testing on clinical care in neonatal diabetes: An international cohort study. Lancet 2015;386:957–63.
4. Chapla A, Murthyunjaya MD, Asha HS, Varghese D, Varshney M, Vasan SK et al. Maturity onset diabetes of the young in India - a distinctive mutation pattern identified through targeted next-generation sequencing. Clin Endocrinol 2015;82:533-42.
5. Rabbone J, Barbetti F, Gentilella R, Mossetto G, Bonfanti R, Maffeis C, et al. Insulin therapy in neonatal diabetes mellitus: A review of the literature. Diabetes Res Clin Pract 2017;129:126–35.
6. Barone JV, Tillman EM, Ferry RJ. Treatment of transient neonatal diabetes mellitus with subcutaneous insulin glargine in an extremely low birth weight neonate. J Pediatr Pharmacol Ther 2011;16:291–7.
7. Jain V, Satapathy A, Yadav J, Sharma R, Radha V, Mohan V, et al. Clinical and molecular characterization of children with neonatal diabetes mellitus at a tertiary care center in northen India. Indian Pediatr 2017;54:467–71.
8. Marin MT, Coffey ML, Beck JK, Dasari PS, Allen R, Krishnan S. A novel approach to the management of neonatal diabetes using sensor-augmented insulin pump therapy with threshold suspend technology at diagnosis. Diabetes Spectr 2016;29:176–9.
9. Gruulich-Henn J, Wagner V, Thon A, Schober E, Marg W, Kapellen TM, et al. Entries and frequency of neonatal diabetes: Data from the diabetes documentation and quality management system (DPV). Diabet Med 2010;27:709–12.
10. Lemelman MB, Letourneau L, Greeley SAW. Neonatal diabetes mellitus: An update on diagnosis and management. Clin Perinatol 2018;45:41–59.
11. Ganesh R, Suresh N, Vasanthi T, Ravikumar KG. Neonatal diabetes: A case series. Indian Pediatr 2017;54:33–6.
12. Wirth M, Jelliman J, Jellimann S, Hascoet J. Neonatal diabetes mellitus: Improved screening and early management of an underestimated disease. Clin Case Rep 2017;6:18–22.
13. Denkboy Öngen Y, Eren E, Demirbaş Ö, Sobi E, Ellard S, De Franco E, et al. Genotype and phenotype heterogeneity in neonatal diabetes: A single centre experience in Turkey. J Clin Res Pediatr Endocrinol 2021;13:80–7.
14. Russo L, Iafusco D, Brescianini S, Nocerino V, Bizzarri C, Toni S, et al. Permanent diabetes during the first year of life: Multiple gene screening in 54 patients. Diabetologia 2011;54:1693–701.
15. Jahnavi S, Poovazhagi V, Mohan V, Bodhini D, Raghupathy P, Amutha A, et al. Clinical and molecular characterization of neonatal diabetes and monogenic syndromic diabetes in Asian Indian children. Clin Genet 2013;83:439–45.
16. Demirbilek H, Arya VB, Ozbek MN, Houghton JAL, Baran RT, Akar M, et al. Clinical characteristics and molecular genetic analysis of 23 patients with neonatal diabetes from the South-Eastern region of Turkey: Predisposition of non-KATP channel mutations. Eur J Endocrinol 2015;172:697–705.
17. Dalvi NNH, Shaikh ST, Shivane VK, Lila AR, Bandgar TR, Shah NS. Genetically confirmed neonatal diabetes: A single centre experience. Indian J Pediatr 2017;84:86–8.
18. Nayak S, Sarangi AN, Sahoo SK, Mangla P, Tripathy M, Rao S, et al. Neonatal diabetes mellitus: Novel mutations. Indian J Pediatr 2021;88:785–92.
19. Laimon W, Aboelenin HM, El Tantawi NT. Clinical characteristics, outcome, and predictors of neurologic sequelae of persistent congenital hyperinsulism: A single tertiary center experience. Pediatr Diabetes 2021;22:388–99.
20. Rubio-Cabezas O, Patch A-M, Minton JA, Flanagan SE, Edghill EL, Hussain K, et al. Wolcott-Rallison syndrome is the most common genetic cause of permanent neonatal diabetes in consanguineous families. J Clin Endocrinol Metab 2009;94:4162–70.
21. Lakshmanan NK, Pavihathan PV, Bhavani N, Abraham N, Kumar H, Nair V, et al. Monogenic diabetes: A single center experience from South India. Pediatr Diabetes 2021;22:75–81.
22. Rubio-Cabezas O, Minton JAL, Caswell R, Shield JP, Deiss D, Sumnik Z, et al. Clinical heterogeneity in patients with FOXP3 mutations presenting with permanent neonatal diabetes. Diabetes Care 2009;32:111–6.
Appendix 1: Thirty gene next-generation genetic sequencing (NGS) panel for neonatal diabetes includes HNF4A, GCK, HNF1A, PDX1, HNF1B, NEUROD1, KLF11, CEL, PAX4, INS, BLK, KCNJ11, ABCC8, AKT2, CISD2, CP, EIF2AK3, GATA6, GLUD1, HADH, IER3IP1, INSR, NEUROG3, PTF1A, RFX6, SLC2A2, WFS1, ZFP57, GLIS3, FOXP3 genes.